Frontlight ResearchEarly access
TerminatedPhase 2
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 5 people enrolled
- Started
- 8 Mar 2022
- Ended
- 26 Aug 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cytarabine
- Record updated
- 16 January 2025
- Why it stopped
- PI decision to close study early due to limited data due to accrual goal not being met
Who can take part
- Age
- 61 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Both males and females ≥ 61 years of age
- A clinical diagnosis of de novo, non-M3 acute myeloid leukemia (AML) confirmed by greater than 20% blasts in peripheral blood or on diagnostic bone marrow biopsy who have completed intensive induction chemotherapy and are confirmed in complete remission #1 (defined by < 5% myeloblasts on recovery bone marrow biopsy, Absolute neutrophil count > 1000/uL and platelets > 100x103/uL) and able to receive HiDAC consolidation #1
- Patients on the prospective arm must be willing to have labs/clinic visits at UF Health Shands approximately every 48 hours +/- 24 hours after discharge from chemotherapy admission to be included. If prospective subjects cannot be followed at the UF site then telephone visits are allowed to follow for toxicity and transfusions. Records can be requested from subject's local physician office
- Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures. For subjects on the historical arm, there will be a waiver of informed consent (as these patients may be deceased or not be available for retrospective consent)
Who cannot take part
- Patients receiving, received, or who will receive a FLT3 inhibitor
- Patients receiving, received, or who will receive an IDH1 or IDH2 inhibitor
- For historical arm, subjects will be excluded if adequate data is not available in electronic medical record (e.g., if patient was followed by their local oncologist between chemotherapy cycles and labs/transfusions/clinic notes, etc. are not available)
- Secondary AML (documented history of antecedent hematological disorder, such as myelodysplastic syndrome or therapy-related AML) or chronic myeloid leukemia (CML) in blast crisis
- Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
- Serum creatinine greater than 2 mg/dL
- History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician
- Age < 61 years
- Patients unable to provide informed consent for prospective arm
- Karnofsky performance status of 40 or less at study entry
Where in United States
- University of FloridaGainesville, United States
About the trial
What the trial wants to find out
This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, and 5 of each cycle, in patients 61 years and older with de novo acute myeloid leukemia (AML).
The 2 groups in the trial
- Prospective HiDAC Treatment (HiDAC 123)Treatment being tested
Subject on this arm will be treated with HiDAC prospectively.
Treatment: Cytarabine
- Historical HiDAC Treatment (HiDAC 135)Other group
Subjects on this arm will be historical controls who have previously received treatment with HiDAC.
Treatment: Cytarabine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) in Complete Remission
- Record updated
- 16 January 2025